Why this ASX 200 blue chip stock could outperform CBA

Analysts think this blue chip is a better buy than CBA.

| More on:
Two brokers analysing stocks.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Strong first quarter growth in life sales and solid capitalisation make this ASX 200 blue chip an attractive investment option.
  • Potential regulatory changes could positively impact its financial outlook by reducing annuity liabilities and required capital.
  • Analysts forecast a 15.5% potential upside and a 19% total return, supported by favourable regulatory benefits and growth opportunities.

Commonwealth Bank of Australia (ASX: CBA) shares are a popular option for blue chip investors.

But given how expensive the big four bank's shares are following strong gains in recent years, the upside from here could be very limited.

Instead, investors might get better returns from the ASX 200 blue chip stock in this article.

Which ASX 200 blue chip stock?

The stock we are going to look at today is annuities company Challenger Ltd (ASX: CGF).

Its shares may be close to a 52-week high, but the team at Bell Potter doesn't believe it is too late to invest. Especially given the release of a strong first quarter update. It said:

The quarterly updates, cover life new business sales, FUM flows and capital, adequacy. Life sales were up 4% year-on-year, helped by lifetime annuities and institutional fixed term annuities. Funds management FUM was weaker, down 3% for the quarter, with $2.3bn of positive market moves offset by $4.9bn in outflows. Challenger Life is strongly capitalised with a PCA ratio of 1.58 times.

Outside this, Bell Potter highlights that potential changes to rules from APRA could be a big positive for Challenger in the near term.

We discuss the illiquidity premium, noting the restrictiveness of the current rules, and consider some of the proposals being considered by APRA. We expect the new standard will allow a higher discount rate and will be more representative of the assets held – including longer dated corporate bonds and a wider range of issuers. The benefit should lead to a reduction in CGF's annuity liabilities (c$16bn at FY25) and could lead to a reduction to the $2.8bn of required capital, particularly asset charges (c$2bn) and stress scenarios (c$0.5bn).

Potential double-digit returns

According to the note, the broker has retained its buy rating on the ASX 200 blue chip stock with an improved price target of $10.25 (from $9.50).

Based on its current share price of $8.87, this implies potential upside of 15.5% over the next 12 months.

In addition, the broker is forecasting a fully franked dividend yield of 3.5%. This boosts the total potential return to 19%.

Commenting on its recommendation, Bell Potter said:

The medium term buy case is supported by both the freeing of capital from the APRA proposals and growth opportunities as Retiring Australians are offered advice and products to achieve an optimal retirement income. A small increase in the take up of annuities, with more favourable capital rules could dramatically increase the long-term growth of CGF. We expect positive news flow before the year-end. Despite a slightly mixed Q1, we increase our Target Price to $10.25/sh and maintain our BUY recommendation.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Challenger. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

Doctor sees virtual images of the patient's x-rays on a blue background.
Blue Chip Shares

Is now the time to buy Pro Medicus shares?

After a 13% pullback, Pro Medicus shares are back in focus. Is this weakness an opportunity?

Read more »

Two strong women battle it out in the boxing ring.
Investing Strategies

Why these 2 battered ASX 200 stocks could shine in 2026

Bruised this year, but analysts see the heavyweight shares bounce back in 2026.

Read more »

A smiling woman holds a Facebook like sign above her head.
Blue Chip Shares

CSL and more blue-chip ASX 200 bargains I'd buy before 2026

Here's why I think these shares could be cheap buys before the end of the year.

Read more »

A happy couple drinking red wine in a vineyard.
Blue Chip Shares

What can investors expect from Treasury Wines' update tomorrow?

Tomorrow’s announcement is shaping up to be one of the most consequential updates in years for Treasury Wine Estates.

Read more »

man in old fashioned suit and hat looking through magnifying glass
Blue Chip Shares

Is the CSL share price a generational bargain at $180?

CSL shares are currently trading near a 7-year low.

Read more »

Machinery at a mine site.
Blue Chip Shares

BHP signs US$2 billion deal: Here's the key takeaway

Let’s take a look at what was announced.

Read more »

Business people discussing project on digital tablet.
Blue Chip Shares

Buy, hold, sell: Medibank, Qantas, and Xero shares

Let's see what analysts are saying about these popular blue chip shares.

Read more »

Man holding out $50 and $100 notes in his hands, symbolising ex dividend.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

Defensive businesses with big yields could be strong choices today…

Read more »